Cartesian announces Phase 2b trial of Descartes-08 achieved primary endpoint

Cartesian Therapeutics announced the presentation of data from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis, MG, during the 2024 Myasthenia Gravis Foundation of America, MGFA, Scientific Session of the American Association of Neuromuscular and Electrodiagnostic Medicine, AANEM, Annual Meeting being held today in Savannah, Georgia. Positive topline results from the trial were previously announced in July 2024. The trial achieved its primary endpoint with statistical significance in the pre-specified modified intent-to-treat efficacy population, with 71% of patients treated with Descartes-08 observed to have 5-point or greater improvements in MG Composite score at Month 3 compared to 25% of patients treated with placebo. Responders that reached their four-month and six-month assessments were observed to have deep, durable, and clinically meaningful improvements in their MGC severity scores. Descartes-08 was observed to have a favorable safety profile supporting outpatient administration without the need for lymphodepleting chemotherapy.